Scribd Logo
Carica

Benvenuto in Scribd!

  • Mitolytix Novel Biomolecule Converts Malignant Phenotype To Benign Status

    Caricato da

    PR.com
    12 visualizzazioni1 pagina
    A new biomolecule developed my Mitolytix Research, referred to as a "Catalyst," significantly induce necrosis of malignant tumors without histological changes in adjacent nontumorous tissue. The objective is tumor “normalization,” in contrast to “expeditious tumor destruction.” While some similarities between the tumor response of chemo-radiotherapy and the catalyst are observed, several differences are noted.

    Titolo originale

    Mitolytix Novel Biomolecule Converts Malignant Phenotype to Benign Status

    Copyright

    © © All Rights Reserved

    Hai trovato utile questo documento?

    Questo contenuto è inappropriato?

    Segnala questo documento
    A new biomolecule developed my Mitolytix Research, referred to as a "Catalyst," significantly induce necrosis of malignant tumors without histological changes in adjacent nontumorous tissue. The objective is tumor “normalization,” in contrast to “expeditious tumor destruction.” While some similarities between the tumor response of chemo-radiotherapy and the catalyst are observed, several differences are noted.

    Copyright:

    © All Rights Reserved
    Segnala contenuti inappropriati
    12 visualizzazioni1 pagina

    Mitolytix Novel Biomolecule Converts Malignant Phenotype To Benign Status

    Caricato da

    PR.com
    A new biomolecule developed my Mitolytix Research, referred to as a "Catalyst," significantly induce necrosis of malignant tumors without histological changes in adjacent nontumorous tissue. The objective is tumor “normalization,” in contrast to “expeditious tumor destruction.” While some similarities between the tumor response of chemo-radiotherapy and the catalyst are observed, several differences are noted.

    Copyright:

    © All Rights Reserved
    Segnala contenuti inappropriati
    di 1

    <B>FPDF error: </B>Unsupported image type: gif

    Potrebbero piacerti anche